+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Hereditary Angioedema (HAE) - Pipeline Review, H1 2015

  • ID: 3293084
  • Report
  • May 2015
  • 78 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • CSL Limited
  • Dyax Corp.
  • iBio, Inc.
  • Pharming Group N.V.
  • Ra Pharmaceuticals, Inc.
  • Shire Plc
  • MORE
Hereditary Angioedema (HAE) - Pipeline Review, H1 2015

Summary

This, ‘Hereditary Angioedema (HAE) - Pipeline Review, H1 2015’, provides an overview of the Hereditary Angioedema (HAE)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hereditary Angioedema (HAE), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hereditary Angioedema (HAE) and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hereditary Angioedema (HAE)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hereditary Angioedema (HAE) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hereditary Angioedema (HAE) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hereditary Angioedema (HAE) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hereditary Angioedema (HAE)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hereditary Angioedema (HAE) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

Loading
LOADING...

3 of 5

FEATURED COMPANIES

  • CSL Limited
  • Dyax Corp.
  • iBio, Inc.
  • Pharming Group N.V.
  • Ra Pharmaceuticals, Inc.
  • Shire Plc
  • MORE
List of Tables
List of Figures
Introduction
REPORT COVERAGE
Hereditary Angioedema (HAE) Overview
Therapeutics Development
Pipeline Products for Hereditary Angioedema (HAE) - Overview
Pipeline Products for Hereditary Angioedema (HAE) - Comparative Analysis
Hereditary Angioedema (HAE) - Therapeutics under Development by Companies
Hereditary Angioedema (HAE) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Hereditary Angioedema (HAE) - Products under Development by Companies
Hereditary Angioedema (HAE) - Companies Involved in Therapeutics Development
BioCryst Pharmaceuticals, Inc.
Cevec Pharmaceuticals GmbH
CSL Limited
Dyax Corp.
Global Blood Therapeutics, Inc.
iBio, Inc.
Isis Pharmaceuticals, Inc.
Pharming Group N.V.
Ra Pharmaceuticals, Inc.
Shire Plc
Hereditary Angioedema (HAE) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
BCX-4161 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BCX-7353 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BEL-0215 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C1 esterase inhibitor (human) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C1 esterase inhibitor (human) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C1 esterase inhibitor (recombinant) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C1 esterase inhibitor (recombinant) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CSL-312 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DX-2930 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
icatibant acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ISIS-PKKRx - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein to Inhibit C1-esterase for Hereditary Angioedema - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule 2 to Inhibit Plasma Kallikrein for Hereditary Angioedema - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Hereditary Angioedema - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptide to Inhibit Kallikrein for Hereditary Angioedema - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hereditary Angioedema (HAE) - Recent Pipeline Updates
Hereditary Angioedema (HAE) - Dormant Projects
Hereditary Angioedema (HAE) - Dormant Projects
Hereditary Angioedema (HAE) - Product Development Milestones
Featured News & Press Releases
Apr 09, 2015: Dyax to Participate in the 14th Annual Needham Healthcare Conference
Mar 31, 2015: Dyax Announces Positive Results from Phase 1b Clinical Trial of DX-2930
Feb 24, 2015: ISIS Pharmaceuticals Reports Positive Phase 1 Data Demonstrating ISIS-PKK Rx Produces Significant Reductions in Prekallikrein Levels
Feb 02, 2015: CEVEC: CAP Derived Recombinant C1 Inhibitor Matches Berinert in Animal Study
Jan 08, 2015: Pharming and Salix Announce First Patient Treated in Clinical Study of Ruconest for Prophylaxis of Hereditary Angioedema
Dec 18, 2014: Dyax First-in-Human Trial for DX-2930 Conducted by Vince and Associates Clinical Research Featured in the Annals of Allergy, Asthma & Immunology
Nov 04, 2014: Pharming Confirms Receipt Of US$20 Million Milestone Payment From Salix Pharmaceuticals
Nov 03, 2014: Salix and Pharming Announce the Launch of RUCONEST in the U.S. for the Treatment of Acute Angioedema Attacks in Patients with Hereditary Angioedema (HAE)
Nov 03, 2014: Dyax Announces Expansion of Phase 1b Clinical Trial for DX-2930
Oct 13, 2014: Pharming and Swedish Orphan Biovitrum Amend and Extend Ruconest Distribution Agreement
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Hereditary Angioedema (HAE), H1 2015
Number of Products under Development for Hereditary Angioedema (HAE) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Hereditary Angioedema (HAE) - Pipeline by BioCryst Pharmaceuticals, Inc., H1 2015
Hereditary Angioedema (HAE) - Pipeline by Cevec Pharmaceuticals GmbH, H1 2015
Hereditary Angioedema (HAE) - Pipeline by CSL Limited, H1 2015
Hereditary Angioedema (HAE) - Pipeline by Dyax Corp., H1 2015
Hereditary Angioedema (HAE) - Pipeline by Global Blood Therapeutics, Inc., H1 2015
Hereditary Angioedema (HAE) - Pipeline by iBio, Inc., H1 2015
Hereditary Angioedema (HAE) - Pipeline by Isis Pharmaceuticals, Inc., H1 2015
Hereditary Angioedema (HAE) - Pipeline by Pharming Group N.V., H1 2015
Hereditary Angioedema (HAE) - Pipeline by Ra Pharmaceuticals, Inc., H1 2015
Hereditary Angioedema (HAE) - Pipeline by Shire Plc, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Hereditary Angioedema (HAE) Therapeutics - Recent Pipeline Updates, H1 2015
Hereditary Angioedema (HAE) - Dormant Projects, H1 2015

List of Figures
Number of Products under Development for Hereditary Angioedema (HAE), H1 2015
Number of Products under Development for Hereditary Angioedema (HAE) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015
Note: Product cover images may vary from those shown
4 of 5
BioCryst Pharmaceuticals, Inc.
Cevec Pharmaceuticals GmbH
CSL Limited
Dyax Corp.
Global Blood Therapeutics, Inc.
iBio, Inc.
Isis Pharmaceuticals, Inc.
Pharming Group N.V.
Ra Pharmaceuticals, Inc.
Shire Plc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll